title: Wayne Fenton's impact on industry.
authors.affiliation: a.breier@lilly.com
authors.forename: Alan
authors.initials: A
authors.lastname: Breier
authors.forename: Larry
authors.initials: L
authors.lastname: Alphs
authors.forename: Brendon
authors.initials: B
authors.lastname: Binneman
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy*; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D049674:History, 21st Century; D006801:Humans; D008396:Maryland; D009315:National Institute of Mental Health (U.S.) / Q000266:history; D011570:Psychiatry / Q000266:history; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D014150:Antipsychotic Agents